Determinants of the cost of health services used by veterans with HIV

Medical Care

Volumn 49, Issue 9, 2011, Pages 848-856

  Barnett, Paul G ^a   Chow, Adam ^a   Joyce, Vilija R ^a   Bayoumi, Ahmed M ^b,c   Griffin, Susan C ^d   Nosyk, Bohdan ^e   Holodniy, Mark ^a   Brown, Sheldon T ^f   Sculpher, Mark ^d   Anis, Aslam H ^g   Owens, Douglas K ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF YORK   (United Kingdom)

^e CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

antiretroviral therapy; cost; HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COMORBIDITY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MENTAL DISEASE; PATIENT COMPLIANCE; PHARMACY; PRIORITY JOURNAL; SUBSTANCE ABUSE; VETERAN; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DRUG COSTS; DRUG RESISTANCE, MULTIPLE; HEALTH CARE COSTS; HIV INFECTIONS; HOSPITAL COSTS; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; UNITED STATES; VETERANS;

EID: 80052175869     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31821b34c0     Document Type: Article

References (36)

1. Keiser P, Kvanli MB, Turner D, et al. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:28-33. (Pubitemid 29045466)
2. Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. Aids. 1999;13:963-969. (Pubitemid 29240192)
3. Mole L, Ockrim K, Holodniy M. Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center. Pharmacoeconomics. 1999;16:307-315. (Pubitemid 29434158)
4. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344:817-823. (Pubitemid 32222161)
5. Anis AH, Hogg RS, Wang XH, et al. Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy. Pharmacoeconomics. 1998;13:697-705. (Pubitemid 28247661)
6. Farnham PG. Do Reduced Inpatient Costs Associated with Highly Active Antiretroviral Therapy (HAART) Balance the Overall Cost for HIV Treatment? Appl Health Econ Health Policy. 2010;8:75-88.
7. Gardner EM, Maravi ME, Rietmeijer C, et al. The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care. Appl Health Econ Health Policy. 2008;6:145-155.
8. Hellinger FJ. Economic models of antiretroviral therapy: searching for the optimal strategy. Pharmacoeconomics. 2006;24:631-642. (Pubitemid 43998816)
9. Hellinger FJ, Encinosa WE. Antiretroviral therapy and health care utilization: a study of privately insured men and women with HIV disease. Health Serv Res. 2004;39:949-967. (Pubitemid 38924687)
10. Schackman BR, Gebo KA,0 Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44:990-997. (Pubitemid 44674030)
11. Jing Y, Klein P, Kelton CM, et al. Utilization and spending trends for antiretroviral medications in the US Medicaid program from 1991 to 2005. AIDS Res Ther. 2007;4:22.
12. Levy AR, James D, Johnston KM, et al. The direct costs of HIV/AIDS care. Lancet Infect Dis. 2006;6:171-177. (Pubitemid 43267642)
13. Chen RY, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis. 2006;42: 1003-1010.
14. Hill AM, Smith C. Analysis of treatment costs for HIV RNA reductions and CD4 increases for darunavir versus other antiretrovirals in treatmentexperienced, HIV-infected patients. HIV Clin Trials. 2007;8:121-131. (Pubitemid 47121757)
15. Krentz HB, Gill MJ. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006. HIV Med. 2008;9: 721-730.
16. Floris-Moore M, Lo Y, Klein RS, et al. Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;34:331-337. (Pubitemid 37377369)
17. Goulet JL, Fultz SL, Rimland D, et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis. 2007;45:1593-1601. (Pubitemid 351411845)
18. Center for Quality Management in Public Health. The State of Care for Veterans with HIV/AIDS. Palo Alto, CA: US Department of Veteran Affairs, Public Health Strategic Health Care Group; 2009.
19. Kyriakides TC, Babiker A, Singer J, et al. An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Control Clin Trials. 2003;24:481-500. (Pubitemid 36831050)
20. Wagner TH, Chen S, Barnett PG. Using average cost methods to estimate encounter-level costs for medical-surgical stays in the VA. Med Care Res Rev. 2003;60:15S-36S. (Pubitemid 36993492)
21. Willan AR, O'Brien BJ. Cost prediction models for the comparison of two groups. Health Econ. 2001;10:363-366. (Pubitemid 32605739)
22. Phibbs CS, Bhandari A, Yu W, et al. Estimating the costs of VA ambulatory care. Med Care Res Rev. 2003;60:54S-73S. (Pubitemid 36993495)
23. Yu W, Ravelo A, Wagner TH, et al. The relationships among age, chronic conditions, and healthcare costs. Am J Managed Care. 2004; 10:909-916. (Pubitemid 40040887)
24. Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57:1107-1110. (Pubitemid 39451804)
25. Render ML, Nowak J, Hammond EK, et al. Methods for estimating and comparing VA outpatient drug benefits with the private sector. Med Care. 2003;41:II61-II69.
26. United States Congress. Congressional Budget Office. Prices for brandname drugs under selected federal programs. CBO Paper; 2005.
27. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20:461-494. (Pubitemid 32515166)
28. Box GEP, Cox DR. An analysis of transformations. J Royal Statistic Soc Series B. 1964;26:211-252.
29. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med. 1991;10:585-598.
30. US Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. [166 pp.] 2011. Available at: http://www.aidsinfo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf.
31. Beck EJ, Harling G, Gerbase S, et al. The cost of treatment and care for people living with HIV infection: implications of published studies, 1999-2008. Curr Opin HIV AIDS. 2010;5:215-224.
32. Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS. 2010;24:2705-2715.
33. Heffler S, Nuccio O, Freeland M. An overview of the NHEA with implications for cost analysis researchers. Med Care. 2009;47:S37-S43.
34. Hellinger FJ. The changing pattern of hospital care for persons living with HIV: 2000 through 2004. J Acquir Immune Defic Syndr. 2007;45:239-246. (Pubitemid 46869819)
35. Rothbard AB, Metraux S, Blank MB. Cost of care for Medicaid recipients with serious mental illness and HIV infection or AIDS. Psychiatr Serv. 2003;54:1240-1246. (Pubitemid 37055985)
36. Roberts RR, Kampe LM, Hammerman M, et al. The cost of care for patients with HIV from the provider economic perspective. AIDS Patient Care STDS. 2006;20:876-886. (Pubitemid 46106074)